您当前的位置：

Ribavirin. (Synonyms: 利巴韦林; Ribasphere)

目录号: PC16706 纯度: ≥98%

CAS No. :36791-04-5

商品编号	规格	价格	会员价
PC16706-100mg	100mg	¥600.00	请登录
PC16706-200mg	200mg	¥840.00	请登录
PC16706-10mM (in 1mL DMSO)	10mM (in 1mL DMSO)	¥600.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称

Ribavirin.

中文别名

利巴韦林;病毒唑;1-beta-D-呋喃核糖基-1H-1,2,4-三氮唑-3-羧酰胺;1-B-D呋喃核糖-1,2,4-三氮唑-3-羟酰胺;三氮唑核苷;1-β-D-呋喃核糖-1,2,4-三氮唑-3-羟酰胺;三氨唑核苷;1-Β-D-呋喃核糖苷-1H-1,2,4-三氮唑-3-羧酰胺;三唑核苷;酰胺三嗪核苷;利巴韦林原粉;Ribavirin 利巴韦林;利巴韦林 USP 31 CP2005;利巴韦林 USP标准品;利巴韦林标准品;利巴韦林.;利巴韦林-13C2;利培酮;三唑核苷 EP标准品;脂肪酸甘油酯;1-β-D-呋喃核糖-1,2,4-三氮唑-3;1-beta-D-呋喃核糖基-1H-1,2,4,-三氮唑-3-羧酰胺

英文名称

Ribavirin

英文别名

ribavirin;1-((2R,3R,4S,5R)-3,4-DIHYDROXY-5-HYDROXYMETHYL-TETRAHYDRO-FURAN-2-YL)-1H-[1,2,4]TRIAZOLE-3-CARBOXYLIC ACID AMIDE;1-BETA-D-RIBOFURANOSYL-1,2,4-TRIAZOLE-3-CARBOXAMIDE;1-BETA-D-RIBOFURANOSYL-1,2,4-TRIAZOLE-3-CAROXAMIDE;1-BETA-D-RIBOFURANOSYL-1H-1,2,4-TRIAZOLE-3-CARBOXAMIDE;biopolymers;D-RIBAVIRIN;ICN-1229;LEVOVIRIN;REBETOL;rtca;tribavirin;vilona;VIRAMID;VIRAZID;VIRAZOLE;ribamidyl;varazid;Ribavirine;1-(β-D-Ribofuranosyl)-1,2,4-triazole-3-carboxamide;1-beta-d-ribofuranosyl-2;1-β-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide;1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide;4-triazole-3-carboxamide;Copegus;Ravanex;RTC;virazol;[ "" ];Ribaviri;Ribasphere;Ribamidil;Ribamide;Rebetron;Ribavirin Capsules;Ribavirinum;Ribavirina;Ribavirinum [INN-Latin];Ribavirine [INN-French];Ribavirina [INN-Spanish];SCH 18908;Ribavirin (Copegus);1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4

Cas No.

36791-04-5

分子式

C₈H₁₂N₄O₅

分子量

244.20

包装储存

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

生物活性

Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV. Ribavirin also has anti-orthopoxvirus and anti-variola activities.

性状

Solid

体外研究(In Vitro)

Treatment of LPS-stimulated microglia with 5, 10 and 20 μM Ribavirin (ICN-1229) induces reduction of NO₂ levels for 43% (p<0.05), 53% (p<0.05) and 59% (p<0.05), respectively. Ribavirin (ICN-1229) (10 mM) insignificantly decreases the cell surface area in non-stimulated culture, but significantly reduces cell surface area (by 32%, p<0.05) in LPS-stimulated microglia. Ribavirin (ICN-1229) is active against DENV, with an EC₅₀ of 3 μM in A549 cells, and combination of CM-10-18 with Ribavirin (ICN-1229) demonstrates a clear enhancement in the reduction of virus replication.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

ALT, AST activities and bilirubin levels are significantly loared by administration of JAT in combination with interferon and Ribavirin (ICN-1229) (p<0.01). JAT, interferon or ribavirin alone with CCl₄, livers appear to exhibit some liver protection against CCl₄ as evident by the presence of normal hepatic cords, absence of necrosis and lesser fatty infiltration. Groups treated with JAT, Peg-interferon and Ribavirin (ICN-1229) separately or in combination shows reduction in the expression of TGF- β and Bax. In the group treated by triple combination of interferon, Ribavirin (ICN-1229), and JAT, the expression level of p53 is markedly reduced. Ribavirin (ICN-1229) capsules (400 mg of ribavirin)-treated Wistar rats show a significant decrease in activin-A and significant increase in follistatin at the serum and liver levels. Ribavirin (ICN-1229) has strong antiviral activity only when ribavirin is combined with either IFN-α or Peg-IFN-α. Ribavirin (40 mg/kg, p.o.) significantly improves the antiviral efficacy of CM-10-18 in mice. Ribavirin (ICN-1229) inhibits DENV virus infection in cultured cells, but it is ineffective in reducing viremia in monotherapy.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature or refrigerated transportation.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

ClinicalTrial

参考文献

[1]. Abdel-Hamid NM, et al. Synergistic Effects of Jerusalem Artichoke in Combination with Pegylated Interferon Alfa-2a and Ribavirin Against Hepatic Fibrosis in Rats. Asian Pac J Cancer Prev. 2016;17(4):1979-85. [Information]

[2]. Refaat B, et al. The effects of pegylated interferon-α and ribavirin on liver and serum concentrations of activin-A and follistatin in normal Wistar rat: a preliminary report. BMC Res Notes. 2015 Jun 26;8:265 [Information]

[3]. Savic D, et al. Ribavirin shows immunomodulatory effects on activated microglia. Immunopharmacol Immunotoxicol. 2014 Dec;36(6):433-41 [Information]

[4]. Chang J, et al. Combination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection 体外研究 and in vivo. Antiviral Res. 2011 Jan;89(1):26-34 [Information]

[5]. Robert O Baker, et al. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 2003 Jan;57(1-2):13-23. [Information]

溶解度数据

体外研究:

H₂O : 100 mg/mL (409.50 mM; Need ultrasonic)

DMSO : 100 mg/mL (409.50 mM; Need ultrasonic)

配制储备溶液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.0950 mL	20.4750 mL	40.9500 mL
5 mM	0.8190 mL	4.0950 mL	8.1900 mL
10 mM	0.4095 mL	2.0475 mL	4.0950 mL

产品不同，其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液；配成溶液后，建议分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，建议在 6 个月内使用，-20°C 储存时，建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

建议依照次序添加每种溶剂： PBS
Solubility: 110 mg/mL (450.45 mM); Clear solution; Need ultrasonic
2.

建议依照次序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (10.24 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (10.24 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH?O 中，得到澄清透明的生理盐水溶液
3.

建议依照次序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (10.24 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (10.24 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
4.

建议依照次序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (10.24 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (10.24 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关文献

相关产品

The molarity calculator equation

The dilution calculator equation